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ABSTRACT
Background Recent studies have demonstrated that
newly diagnosed glucose intolerance is common among
patients with acute myocardial infarction (AMI). The
purpose of this study was to assess the long-term
clinical cardiovascular outcomes in participants with AMI
with abnormal fasting glucose compared with normal
fasting glucose and an abnormal oral glucose tolerance
test (OGTT) compared with a normal OGTT.
Methods A prospective study was performed in 275
consecutive patients with AMI, 85 of whom had pre-
diagnosed diabetes mellitus (DM). Those without DM
were divided into two groups based on the 75 g OGTT at
the time of discharge. Abnormal glucose tolerance (AGT)
was deﬁned as 2 h glucose $140 mg/dl; 78 patients
had normal glucose tolerance (NGT) and 112 had AGT.
The same patients were also reclassiﬁed into the normal
fasting glucose group (NFG; n¼168) or the impaired
fasting glucose group (IFG; n¼22). The association
between the glucometabolic status and long-term major
adverse cardiovascular event rates was evaluated.
Results KaplaneMeier survival curves showed that the
AGT group had a worse prognosis than the NGT group
and an equivalent prognosis to the DM group
(p<0.0005). Cox proportional hazard model analysis
showed that the HR of AGT to NGT for major adverse
cardiovascular event rates was 2.65 (95% CI 1.37 to
5.15, p¼0.004) while the HR of DM to NGT was 3.27
(1.68 to 6.38, p¼0.0005). However, Cox HR of IFG to
NFG for major adverse cardiovascular event rates was
1.83 (0.86 to 3.87), which was not signiﬁcant.
Conclusion In patients with AMI, an abnormal OGTT is
a better risk factor for future adverse cardiovascular
events than impaired fasting blood glucose.
Compared with individuals without diabetes
mellitus (DM), patients with DM have about
a twofold higher risk of short-term mortality after
acute myocardial infarction (AMI).
1 In the current
era in which reperfusion is used, over 90% of
patients with DM survive the early 30-day period
but these patients are prone to markedly increased
mortality after 6 months.
23
Several cohort studies
4e6 have shown that people
with pre-diabetic conditions such as impaired
glucose tolerance (IGT) are at increased risk for
cardiovascular disease. In fact, patients with pre-
diabetic IGT are compromised because they have
atherogenic risk factors which, of course, affect the
coronary arteries.
7 A systematic meta-analysis
based on 20 clinical studies
8 suggested that a blood
glucose concentration even below the threshold for
diagnosing DM is associated with a signiﬁcantly
higher risk of coronary artery disease.
Fasting plasma glucose (FPG) and HbA1c are the
most commonly measured glycaemic parameters
for secondary preventions after the onset of
cardiovascular disease in a clinical setting. Although
the relevance of glycaemic exposure is indisputable,
FPG does not completely explain the risk. The
Diabetes Epidemiology: Collaborative Analysis of
Diagnostic Criteria in Europe study demonstrated
that fasting glucose concentrations alone do not
identify individuals at increased risk of death
and cardiovascular disease associated with hyper-
glycaemia; however, the oral glucose tolerance
test (OGTT) provides additional prognostic
information.
6
Post-challenge hyperglycaemia is an appropriate
model of postprandial hyperglycaemia and is asso-
ciated with an increased risk of coronary artery
disease.
9 10 The Funagata Diabetes Study,
11 a 7-year
prospective study using a Japanese cohort popula-
tion, showed that IGT but not impaired fasting
glucose (IFG) was a risk factor for cardiovascular
disease.
Recently, the GAMI (Glucose Tolerance in
Patients with AMI) study showed that abnormal
glucose tolerance (AGT) determined by the pres-
ence of post-challenge hyperglycaemia was
common among patients with AMI
12 and is a risk
factor for future cardiovascular events.
13 14
However, the measurements of FPG dominate
screening after AMI in current clinical practice. The
aims of this study were twofold: (1) to determine
whether newly diagnosed abnormal glucose regu-
lations affect the long-term clinical outcomes after
AMI; and (2) to assess the long-term clinical
outcome after AMI associated with the fasting
glucose classiﬁcation compared with the 2 h post-
challenge glucose classiﬁcation.
METHODS
Study patients
We enrolled 384 consecutive patients admitted to
the coronary care unit of Kobe City Medical Center
General Hospital, Japan with AMI from August
1997 to December 2000. Individuals aged >80 years
or those with serum creatinine concentrations
>2.0 mg/dl or other in-hospital major adverse
clinical events including cardiogenic shock with
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Acute coronary syndromesmechanical support and emergency coronary artery bypass
grafting were excluded. Of the 384 consecutive patients
screened, 109 patients were excluded because of in-hospital
death (n¼34), stroke (n¼2), emergency coronary artery bypass
surgery (n¼22), LV reconstruction surgery (n¼2), non-fatal LV
rupture (n¼5), recurrent percutaneous coronary intervention
(PCI; n¼3), concomitant disease (n¼6, idiopathic dilated
cardiomyopathy, neoplasm, schizophrenia, hypoxic brain
damage), chronic renal failure (n¼7), >80 years of age (n¼8) and
unwillingness to enter the study (n¼20). Thus, the current
study included 275 patients with AMI.
Protocols
The diagnosis of AMI was based on typical chest pain lasting
more than 30 min, new Q-waves in at least two of the 12
standard leads, changes in the ECG indicating acute ischaemia or
an increase in creatine kinase (CK) concentration to twice the
upper limit of the normal range. The cardiac rehabilitation
programme for each patient was provided during their
administration.
The glucometabolic status of each patient before hospital-
isation was evaluated by medical questionnaire and outpatient
records. Patients were classiﬁed as having previous DM if they
had a recorded history of DM or if they were on a diet or medical
treatment for DM. Patients with persistent elevated fasting
glucose levels ($126 mg/dl) at the time of discharge were also
categorised as having previous DM. In patients without overt
DM, a standard 75 g OGTTwas undertaken at discharge.
The remaining patients were divided into two groups
according to 2 h glucose classiﬁcation adopted by the WHO in
1998
15dnamely, patients were classiﬁed as having newly diag-
nosed DM if their FPG concentrations were <126 mg/dl and 2 h
post-load blood glucose concentrations exceeded 200 mg/dl. IGT
was deﬁned as FPG <126 mg/dl and 2 h blood glucose
140e199 mg/dl. The term AGT was used to describe the pres-
ence of newly detected DM or IGT. Normal glucose tolerance
(NGT) was deﬁned as FPG <126 mg/dl and 2 h blood glucose
<140 mg/dl.
The study population was reclassiﬁed according to only the
FPG classiﬁcation adopted by the WHO in 1998
15 into normal
fasting glucose (NFG), IFG and diabetic groupsdthat is, IFG
was deﬁned by FPG of 110e125 mg/dl and NFG was deﬁned by
FPG <110 mg/dl at the time of discharge.
Patients who received PCI with stent implantation were
started on ticlopidine (100 mg twice a day) and aspirin (81 mg
twice a day) for 2 months. Patients visited the outpatient clinic
monthly for the ﬁrst 6 months, then every 2 or 3 months until
the ﬁnal visit.
Study endpoints and deﬁnitions
Cardiovascular death was deﬁned as death from myocardial
infarction, stroke or sudden death without any obvious reasons.
Acute coronary syndrome (ACS) was deﬁned as new onset or
worsening angina that required hospitalisation and was associ-
ated with ischaemic STsegment abnormalities, any elevation of
cardiac enzymes, or both. Non-fatal myocardial infarction and
ACS were deﬁned as non-fatal myocardial infarction or ACS
occurring >1 month after the primary AMI. The target vessel
was considered to be the infarct-related coronary artery that was
responsible for the AMI at the time of study enrolment. Non-
target vessel revascularisation was deﬁned as any PCI other than
on the target vessel. Non-target vessel revascularisation was
considered to be driven by ischaemia if the stenosis of any vessel
was at least 50% of the diameter of the vessel on the basis of
quantitative coronary angiography in the presence of ischaemic
signs or symptoms. Congestive heart failure during follow-up
was diagnosed using validated criteria.
16
The primary study outcomes included long-term incidence of
a major adverse cardiovascular event (MACE) deﬁned as
cardiovascular death, stroke, non-fatal myocardial infarction or
ACS, non-target vessel revascularisation either by coronary
artery bypass grafting or coronary angioplasty and congestive
heart failure that required hospitalisation. The follow-up infor-
mation was obtained using hospital records or by telephone at
5 years. The primary outcome of the study was evaluated at the
end of December 2005. Information about MACE was obtained
from hospital records or telephone contact with patients,
relatives of patients or the referring physician.
Statistical analysis
Demographic and baseline characteristics are shown as
mean6SD for continuous variables and as numbers and
percentages for categorical variables. Comparisons among the
post-challenge glucose classiﬁcation groups (NGT, AGT, previous
DM) were examined using one-way ANOVA for continuous
variables and c
2 test for categorical variables. In the case of
signiﬁcant F values for ANOVA, the Tukey-Kramer test was used
for multiple comparisons among groups. Comparisons for post-
challenge 2 h glucose levels between NGT and AGTwere made
using the Wilcoxon rank sum test.
The KaplaneMeier method was used to assess the proportion
of patients with events of interest for time-to-event endpoints
that included MACE and composite clinical outcomes. Times-
to-event among the above three groups were compared by log-
rank test. For patients who experienced multiple events, the ﬁrst
event was considered for time-to-event analysis.
The main purpose of the analysis was to examine whether
post-challenge classiﬁcation is a signiﬁcant predictor for MACE
compared with fasting glucose classiﬁcation. In order to examine
independent predictors of MACE, we used a Cox proportional
hazards model. We modelled candidate predictors as univariates
and determined which predictors were signiﬁcant (p<0.20). All
covariates with p values <0.20 were then modelled multi-
variately using a backward procedure to predictors that were
signiﬁcantly related to MACE. Finally, we used two multivariate
models that included post-challenge and fasting glucose classi-
ﬁcations separately and controlled for signiﬁcant predictors. A
two-sided p value of <0.05 was considered statistically signiﬁ-
cant. Statistical analysis was performed using 9.1.3 SAS-Stat
software (SAS Institute).
RESULTS
We enrolled 275 patients, of whom 85 had previously been
diagnosed with DM. The remaining 190 non-DM patients
underwent an OGTTat the time of discharge. Final visits were
completed between September and December 2005. The median
follow-up interval was 5.3 years.
The non-DM patients were divided into two groups according
to the 2 h post-challenge glucose classiﬁcation: 78 with NGTand
112 patients with newly diagnosed AGT (IGT, n¼77; DM,
n¼35). When the fasting glucose classiﬁcation was applied,
however, only 12% of individuals (1 with NGT, 8 with IGTand
13 with newly diagnosed DM) without overt DM were diag-
nosed with IFG. There was only one patient with isolated IFG
(with no IGT). Among patients with newly diagnosed AGT,
only 21 of 112 (19%) had IFG, so the remaining 81% patients
had isolated post-challenge hyperglycaemia.
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Acute coronary syndromesThere were no differences in the prevalence of cardiovascular
risk factors or cardiovascular comorbidity among these three
groups (table 1). Patients with AGT had several differences from
those without AGT including higher values of 2 h glucose and
triglycerides. The types of reperfusion therapy for AMI were
similar among the groups. Subsequent treatments did not differ
signiﬁcantly among the three groups, except for lipid-lowering
agents which were prescribed most frequently in the AGT group
(table 2).
Clinical events in relation to glucometabolic status are
summarised in table 3. Clinical events due to coronary segments
that were not responsible for the primary AMI increased after
l year.Thecardiovascularevent-freesurvivalrateintheAGTgroup
was 70% at 5 years of follow-up, which was signiﬁcantly lower
thantherateintheNGTgroup(87%,p¼0.0085)andequivalentto
that in the pre-diagnosed DM group (60%, p¼0.09 (see ﬁgure 1)).
The cardiovascular event-free survival rate in the IFG group was
63% at 5 years of follow-up, which was lower than the rate in the
NFGgroup(79%,p¼0.08)butnotsigniﬁcantlydifferentfromthat
in the pre-diagnosed DM group (60%, p¼0.87 (see ﬁgure 1)).
The incidence of MACE was related to several variables
identiﬁed by simple Cox regression (table 4). The best prediction
of a future cardiovascular event, according to multiple Cox
regression analysis, was achieved using a model that included
previous coronary artery bypass surgery, prescriptions of statins
and glucometabolic status. In this Cox model the RR of MACE
was 2.65 (95% CI 1.34 to 5.15, p¼0.004) in the AGT group and
3.27 (95% CI 1.68 to 6.38, p¼0.0005) in the pre-diagnosed DM
group compared with the NGT group. However, the Cox HR of
IFG to NFG on MACE was 1.83 (95% CI 0.86 to 3.87), which
was not signiﬁcant.
We also performed a sensitivity analysis after excluding newly
diagnosed DM participants in the AGT group. In the multivar-
iate Cox model the RR of MACE was 2.67 (95% CI 1.32 to 5.42,
p¼0.0064) in the IGT group and 3.20 (95% CI 1.64 to 6.25,
p¼0.0006) in the pre-diagnosed DM group compared with the
NGT group.
DISCUSSION
Our study conﬁrmed the high prevalence of impaired glucose
regulation in patients with AMI. More importantly, most
abnormal glucose regulation was undiagnosed by only the FPG
test, but post-challenge glucometabolic abnormality was one of
the most powerful predictors of long-term cardiovascular events
independent of its magnitude (overt DM vs IGT) or its history
(previously known vs newly diagnosed).
Prevalence of glucose intolerance in patients with AMI
The high prevalence (72%) of impaired glucometabolic status
(previous DM, 31%; newly diagnosed AGT, 41%) was evident in
our study based on patients with AMI in the Japanese popula-
tion. The actual prevalence might be much higher since we
excluded nearly one-third of patients whose medical condition
was complicated by in-hospital adverse cardiovascular events
and/or renal insufﬁciency. Conversely, <30% of patients were
categorised as having normal glucose regulation determined by
the 75 g OGTT 14 days after the onset of AMI when their
cardiovascular condition was fully stabilised. Therefore, consis-
tent with the data from the GAMI study in Sweden,
12
a substantial proportion of patients with AMI might have
abnormal glucose metabolism. Using 134 Japanese patients with
AMI/ACS but with no previous DM (normal levels of HbA1c
and fasting glucose), Hashimoto et al reported that 10% of
subjects had DM and 37% had IGT/IFG using the 75 g OGTT.
17
Taking these ﬁndings together, the prevalence of abnormal
glucometabolic status in Japanese patients with cardiovascular
disease may be equivalent to or higher than that in Caucasian
populations.
12
Table 1 Baseline characteristics of the three patient groups
Normal glucose
tolerance (n[78)
Abnormal glucose
tolerance (n[112)
Diabetes
mellitus (n[85) p Value
Basic characteristics
Age in years (mean, SD) 62.5 (10.0) 61.6 (11.0) 61.9 (9.6) 0.83
Men 60 (77%) 88 (79%) 66 (77%) 0.96
Previous disorders
Myocardial infarction 6 (8%) 15 (13%) 13 (15%) 0.31
Hypertension 43 (55%) 65 (58%) 45 (53%) 0.77
CABG 1 (1%) 2 (2%) 5 (6%) 0.14
PCI 1 (1%) 6 (5%) 3 (4%) 0.34
Stroke 4 (5%) 11 (10%) 3 (4%) 0.18
Current smoker 47 (60%) 70 (63%) 47 (55%) 0.59
Hyperlipidaemia 37 (47%) 75 (67%) 53 (62%) 0.13
Family history of CHD 7 (9%) 9 (8%) 5 (6%) 0.74
Variable (mean, SD)
BMI, kg/m
2 23.4 (3.0) 23.9 (2.7) 23.4 (4.9) 0.54
HbA1c, % 5.1 (0.4) 5.5 (0.6)* 8.0 (1.8)* y <0.0001
Admission blood glucose, mg/dl 149.4 (34.2) 172.8 (57.6)* 286.2 (95.4)* y <0.0001
FPG, mg/dl 93.6 (9.0) 99.0 (12.6) 140.4 (34.2) * <0.0001
2 h plasma glucose, mg/dl 109.8 (30.6) 183.6 (37.8)* NA <0.0001
Cholesterol, mg/dl 196.1 (39.0) 201.9 (30.9) 200.7 (40.9) 0.57
HDL-cholesterol, mg/dl 42.5 (9.7) 40.1 (11.2) 40.1 (9.3) 0.28
LDL-cholesterol, mg/dl 129.3 (35.5) 131.2 (27.0) 132.0 (35.9) 0.89
Triglycerides, mg/dl 122.1 (55.8) 153.1 (68.1)* 143.4 (48.7) 0.003
Data are n (%) unless otherwise indicated.
*p<0.05 vs normal glucose tolerance.
yp<0.05 vs abnormal glucose tolerance.
BMI, body mass index; CABG, coronary artery bypass graft; CHD, coronary heart disease; FPG, fasting plasma glucose; PCI,
percutaneous coronary intervention.
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Acute coronary syndromesIn this study, 12% of individuals without overt DM (1 with
NGT, 8 with IGT, 13 with newly diagnosed DM) were diagnosed
with IFG; thus, the FPG test alone identiﬁed only 10% of
patients with IGTand 37% of those with newly diagnosed DM,
while 90% of patients with IGT and 63% of those with newly
diagnosed with DM would remain undiagnosed.
Patients with IGT were more prevalent than those with IFG
in this study population. This result was consistent with
a previous epidemiological study in Asia.
18 DM and impaired
glucose regulation will be underestimated in Asian populations if
fasting glucose testing alone is used.
Henareh et al reported that eight patients with normal FPG
had DM and 26 patients with normal FPG had IGTaccording to
the OGTT; thus, the FPG test alone identiﬁed only 39% of
patients with DM and 10% of patients with IGT, while
61% of patients with DM and 90% with IGT would remain
undiagnosed.
19
Elevated plasma glucose levels on admission are very common
in patients with AMI and can be the ﬁrst indication of glucose
intolerance.
20 However, elevated plasma glucose levels on
admission, HbA1c and FPG had a low sensitivity to detect
undiagnosed DM. An OGTTappears to be the best test to assess
the presence of previously undiagnosed DM or impaired glucose
regulation in hyperglycaemic patients with AMI.
20 These results
are consistent with our study. Thus, it is clear that the fasting
glucose test cannot replace the OGTT if the ambition is to
identify the group of subjects with pathological glucose toler-
ance. Furthermore, 2 h glucose has been reported to be a better
risk predictor for future cardiovascular events than fasting
glucose.
21
Prognosis of patients with AMI with abnormal glucometabolic
status
The lowest rate of MACE was observed in the group with NGT.
More importantly, there were no differences in the MACE rates
between the newly detected AGT and DM groups during long-
term follow-up after AMI. Our results are consistent with the
GAMI study by investigators in Sweden,
13 although there were
substantial differences in study populations and backgrounds.
These differences included: (1) they did not enter subjects with
established DM; (2) their patients with undiagnosed DM were
deﬁned by blood glucose levels <200 mg/dl at admission; and (3)
most of their patients did not receive acute reperfusion therapy
during the course of their AMI. Therefore, racial differences or
modest differences in study conditions are not likely to have
affected our major ﬁnding that the abnormal glucometabolic
status is a strong predictor of long-term outcomes.
In our study a sensitivity analysis after excluding newly
diagnosed DM participants in the AGT group showed that there
were signiﬁcant differences in the MACE rates between the
newly diagnosed IGT and NGT groups. Our results showing
that baseline IGTafter AMI is an independent risk predictor for
Table 2 Treatment during hospital stay and at discharge of the three patient groups
Normal glucose
tolerance (n[78)
Abnormal glucose
tolerance (n[112)
Diabetes
mellitus (n[85) p Value
Thrombolysis 3 (4%) 3 (3%) 6 (7%) 0.32
Primary PCI
POBA 22 (28%) 30 (27%) 17 (20%) 0.42
Stents 45 (58%) 70 (63%) 51 (60%) 0.80
Aspirin 76 (97%) 110 (98%) 82 (96%) 0.74
Ticlopidine 44 (56%) 66 (59%) 48 (56%) 0.92
b-blockers 60 (77%) 95 (85%) 70 (82%) 0.38
ACE inhibitors 64 (82%) 89 (79%) 74 (87%) 0.38
Calcium channel blockers 14 (18%) 12 (11%) 14 (16%) 0.32
Diuretics 8 (10%) 12 (11%) 13 (15%) 0.53
Statin 20 (26%) 46 (41%) 24 (28%) 0.05
Oral hypoglycemic agents 0 (0%) 20 (18%) 66 (78%) <0.0001
Insulin therapy 0 (0%) 0 (0%) 6 (7%) 0.004
Data are n (%) unless otherwise indicated.
CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; POBA, plain old balloon angioplasty.
Table 3 Events in relation to glucometabolic status
Type of event
Normal fasting
glucose (n[168)
Impaired fasting
glucose (n[22)
Normal glucose
tolerance (n[78)
Abnormal glucose
tolerance (n[112)
Diabetes
mellitus (n[85)
Death
Non-cardiovascular 6 (0) 1 (0) 2 (0) 5 (0) 3 (0)
Cardiovascular 4 (0) 1 (0) 2 (0) 3 (0) 3 (1)
Stroke 6 (2) 0 (0) 2 (0) 4 (2) 2 (1)
Non-fatal MI or ACS 12 (1) 3 (0) 3 (0) 12 (1) 9 (2)
CABG 7 (5) 2 (1) 2 (2) 7 (4) 6 (4)
PCI
TVR 28 (25) 1 (1) 12 (10) 17 (16) 21 (21)
Non-TVR 14 (4) 4 (0) 2 (1) 16 (3) 17 (9)
Heart failure 5 (2) 1 (0) 1 (1) 5 (1) 8 (3)
Peripheral vascular disease 2 (0) 0 (0) 0 (0) 2 (0) 2 (0)
Sum of MACE 48 (14) 11 (1) 12 (4) 47 (11) 45 (20)
The table summarises events that occurred until death or 31 December 2005. Data are numbers (during the ﬁrst year). Each event was recorded only once.
ACS, acute coronary syndrome; CABG, coronary artery bypass graft; MACE, major adverse cardiovascular event; MI, myocardial infarction; PCI, percutaneous coronary intervention; TVR, target
vessel revascularisation.
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Acute coronary syndromesfuture cardiovascular events are consistent with previous
reports.
22
Early detection of abnormal glucometabolic status after AMI
Our data agree with others that patients with post-challenge
abnormal glucose regulation carry an increased risk of cardio-
vascular morbidity and mortality. Early detection of AGTwould
therefore permit the initiation of secondary preventive
programmes in high-risk patients for future cardiovascular
events.
The Diabetes Epidemiology: Collaborative Analysis of Diag-
nostic Criteria in Europe study showed that fasting glucose
levels did not identify individuals at risk whereas abnormal post-
loading 2 h glucose concentrations were quantitative predictors
of mortality.
6 In addition, IGTwas more prevalent than IFG in
almost all age groups in Asian subjects.
18 Without OGTT, the
majority of people with glucose intolerance would remain
unidentiﬁed.
18 In our study, 91 patients (81%) with newly
diagnosed AGT had normal FPG levels; hence, <20% of patients
had apparent IFG. These lines of evidence consistently point to
Figure 1 KaplaneMeier estimate of time to the primary endpoint among the three patient groups: (A) fasting glucose classiﬁcation; (B) post-
challenge glucose classiﬁcation. AGT, abnormal glucose tolerance; DM, diabetes mellitus; IFG, impaired fasting glucose; NFG, normal fasting glucose;
NGT, normal glucose tolerance.
Table 4 Candidate predictors related to major adverse cardiovascular events among the three groups
Variables
Univariate analysis Multivariate analysis
HR (95% CI) p Value HR (95% CI) p Value
FPG classiﬁcation
Normal fasting glucose 1 1
Impaired fasting glucose 1.85 (0.90 to 3.84) 0.0964 1.86 (0.86 to 3.87) 0.116
Previous DM 1.96 (1.24 to 3.12) 0.0043 1.96 (1.21 to 3.16) 0.006
Post-challenge classiﬁcation
Normal glucose tolerance 1 1
Abnormal glucose tolerance 2.48 (1.28 to 4.78) 0.0068 2.65 (1.37 to 5.15) 0.004
Previous DM 3.23 (1.67 to 6.24) 0.0005 3.27 (168 to 6.38) 0.0005
Previous CABG surgery 4.25 (1.83 to 9.84) 0.0009 3.86 (1.65 to 9.04) 0.0018
FPG 1.01 (1.00 to 1.02) 0.001
Admission blood glucose 1.00 (1.00 to 1.01) 0.0181
History of MI 1.87 (1.08 to 3.23) 0.0252
Statins 0.59 (0.35 to 0.99) 0.0452 0.56 (0.33 to 0.94) 0.0293
HbA1c 1.12 (0.99 to 1.26) 0.0516
Previous stroke 1.78 (0.92 to 3.46) 0.0882
Diuretics 1.64 (0.92 to 2.92) 0.0918
Age 1.02 (0.99 to 1.04) 0.1436
Hypertension 1.37 (0.87 to 2.15) 0.1739
Results are from a univariate Cox regression for variables with p<0.20.
CABG, coronary artery bypass graft; DM, diabetes mellitus; FPG, fasting plasma glucose; MI, myocardial infarction.
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Acute coronary syndromesthe critical importance of determining post-loading glucose
levels for the assessment of glucose intolerance, although the
measurements of FPG and HbA1c still dominate screening in
current clinical practice.
23
In our study, patients with AGT had higher levels of triglyc-
erides than those with NGT. Since hypertriglyceridaemia is one
of the established factors contributing to metabolic syndrome,
24
this risk factor together with AGTcould affect outcomes among
patients with AMI. It should be borne in mind that patients
with metabolic syndrome were more common in this particular
group.
Hyperglycaemia after AMI: risk marker or therapeutic target
Elevated plasma glucose levels on admission are very common in
patients with AMI and are associated with a high incidence of
adverse clinical outcomes.
25 Non-DM patients with hyper-
glycaemia on admission have similar death rates to those with
established DM even after risk stratiﬁcation. In fact, hyper-
glycaemic patients without a previous diagnosis of DM may
have a higher short-term morality risk than hyperglycaemic
patients with known DM.
26 In this study the blood glucose
concentration on admission was higher in patients with AGT
than in those with NGT, regardless of the similar value of FPG at
discharge. We did not apply intensive insulin therapy to control
blood glucose. Interventions to rapidly normalise blood glucose
are applied inconsistently and with uncertain utility. Clinical
trials of insulin therapy for AMI can be divided into those with
a primary aim of delivering insulin (insulin focus) and those
with a primary aim of achieving tight glycaemic control
(glycaemia focus). The results of meta-analysis suggest that
treatment with an insulin focus strategy only (without regard to
the glucose level) does not improve mortality after AMI in the
reperfusion era. Nevertheless, it remains possible that control of
hyperglycaemia by insulin infusion with a glycaemia focus
improves mortality after AMI.
27 Blood glucose should be
measured at admission in all cases of AMI, although this is less
important if no speciﬁc treatment was then offered to restore
euglycaemia where necessary. Given that this is an unreliable
marker of pre-existing or subsequent abnormal glucose metab-
olism, all non-DM patients with AMI should later undergo an
OGTT to identify those with undiagnosed DM or impaired
glucose homeostasis.
20 25
Study limitations
First, we did not make repeated evaluations of glucometabolic
status so we do not know how many patients with IGT
developed overt DM during the observation period. Some reports
have shown that baseline IGT is an independent risk predictor
for future cardiovascular events which is not confounded by the
subsequent development of DM.
22 In addition, patients with
a recent myocardial infarction had a high annual incidence rate
of IFG and DM.
28 These results indicate that myocardial
infarction could be a pre-diabetes risk equivalent. Thus, it is
important to detect abnormal glucose regulation in patients
with AMI during the hospital phase. Second, it is difﬁcult to
make any conclusions regarding the utility of fasting glucose
classiﬁcation from this study because there were only 22
patients with IFG. However, most of the patients with undi-
agnosed glucose intolerance were detected by the deﬁnition
adopted by post-challenge glucose classiﬁcation. Third, because
our subjects were mostly Japanese, caution is needed in
extrapolating our results to other ethnic groups. Fourth, the
deﬁnition of AMI and medical treatments after AMI were based
on the local guidelines around that time. Because medical
treatments after AMI are outdated (low use of dual antiplatelet
therapy and statin therapy), caution is needed in extrapolating
our results to the current clinical settings.
Conclusions
Newly diagnosed glucose intolerance (IFG or AGT) predicts
long-term cardiovascular events in patients with AMI. Its
adverse prognostic impact is as large as that of previously
diagnosed DM. When the fasting glucose criteria were applied,
only 12% of individuals without previously diagnosed DM were
diagnosed as having glucose intolerance. Therefore, the fasting
glucose classiﬁcation is not suitable for screening subsequent
high-risk patients with glucose intolerance. Post-challenge
glucometabolic status is a better risk factor for future cardio-
vascular events than the fasting glucose level and may critically
distinguish high-risk individuals.
Since impaired glucose regulation is an important cardiovas-
cular risk factor, the OGTTshould be considered as a routine test
after AMI in patients without known DM.
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